Cargando…

2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience

BACKGROUND: Once a parasitic infection limited to tropical/subtropical regions, as international travel and immigration continues to rise, Strongyloidiasis is now a disease also prevalent in non-endemic regions, including the United States. Its disease spectrum spans from an asymptomatic infection t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vargas-Pena, Coral N, Alyssa Policarpio, Maria, Chan, Bailey, Kladias, Michael, Coyle, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677805/
http://dx.doi.org/10.1093/ofid/ofad500.141
_version_ 1785150216845918208
author Vargas-Pena, Coral N
Alyssa Policarpio, Maria
Chan, Bailey
Kladias, Michael
Coyle, Christina
author_facet Vargas-Pena, Coral N
Alyssa Policarpio, Maria
Chan, Bailey
Kladias, Michael
Coyle, Christina
author_sort Vargas-Pena, Coral N
collection PubMed
description BACKGROUND: Once a parasitic infection limited to tropical/subtropical regions, as international travel and immigration continues to rise, Strongyloidiasis is now a disease also prevalent in non-endemic regions, including the United States. Its disease spectrum spans from an asymptomatic infection to a hyper-infection syndrome, predominantly in patients with HTLV-1 and/or on steroids, where it can be deadly if not recognized early. METHODS: Retrospective descriptive study describing patients who tested positive for Strongyloides stercoralis between 2019-2023 at Jacobi Medical Center, a safety net hospital in Bronx, NYC. Patients were diagnosed with a serum recombinant immunodiagnostic antigen from S. stercoralis-specific larvae. RESULTS: 108 patients were included; the mean age was 53.7+/-16 years, 63% were male. The most common place of birth was Latin America, Caribbean, Mexico in descending order. Prolonged steroid use (more than 1 week) reported by 7.4% and 8.3% had been exposed to chemotherapy/cytotoxic drugs. 92.5% of individuals were asymptomatic. Reason for testing was eosinophilia in 56.5% and migrant screening in 36.1%. The remaining (8%) patients were tested for diarrhea, urticaria and abdominal pain. Infectious diseases performed 76% of testing while primary care tested 15%. Mean time from immigration was 19.9 years. Stool testing was performed in 60 patients; larvae were seen 21.7% of these. Eosinophilia (abs >500/uL) was found in 70.4% of cases. Of the 29.6% w/o eosinophilia, 64.6 % of individuals reported an outdoor toilet. Ivermectin was given to 98% of cases. [Figure: see text] [Figure: see text] CONCLUSION: Most cases were asymptomatic and identified on screening. Eosinophilia was seen in 2/3 of cases of strongyloidiasis, but 1/3 did not have eosinophilia. Larvae were reported in 21% of patients who had a stool for O/P underscoring the importance of establishing this diagnosis with serology. In patients without eosinophilia, strongyloidiasis should be considered if living conditions in country of birth put them at risk. As expected, patients had been in the US for many years prior to testing and only 15% of patients were screened by primary care. Increased awareness of the disease must be encouraged, especially amongst primary care physicians. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106778052023-11-27 2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience Vargas-Pena, Coral N Alyssa Policarpio, Maria Chan, Bailey Kladias, Michael Coyle, Christina Open Forum Infect Dis Abstract BACKGROUND: Once a parasitic infection limited to tropical/subtropical regions, as international travel and immigration continues to rise, Strongyloidiasis is now a disease also prevalent in non-endemic regions, including the United States. Its disease spectrum spans from an asymptomatic infection to a hyper-infection syndrome, predominantly in patients with HTLV-1 and/or on steroids, where it can be deadly if not recognized early. METHODS: Retrospective descriptive study describing patients who tested positive for Strongyloides stercoralis between 2019-2023 at Jacobi Medical Center, a safety net hospital in Bronx, NYC. Patients were diagnosed with a serum recombinant immunodiagnostic antigen from S. stercoralis-specific larvae. RESULTS: 108 patients were included; the mean age was 53.7+/-16 years, 63% were male. The most common place of birth was Latin America, Caribbean, Mexico in descending order. Prolonged steroid use (more than 1 week) reported by 7.4% and 8.3% had been exposed to chemotherapy/cytotoxic drugs. 92.5% of individuals were asymptomatic. Reason for testing was eosinophilia in 56.5% and migrant screening in 36.1%. The remaining (8%) patients were tested for diarrhea, urticaria and abdominal pain. Infectious diseases performed 76% of testing while primary care tested 15%. Mean time from immigration was 19.9 years. Stool testing was performed in 60 patients; larvae were seen 21.7% of these. Eosinophilia (abs >500/uL) was found in 70.4% of cases. Of the 29.6% w/o eosinophilia, 64.6 % of individuals reported an outdoor toilet. Ivermectin was given to 98% of cases. [Figure: see text] [Figure: see text] CONCLUSION: Most cases were asymptomatic and identified on screening. Eosinophilia was seen in 2/3 of cases of strongyloidiasis, but 1/3 did not have eosinophilia. Larvae were reported in 21% of patients who had a stool for O/P underscoring the importance of establishing this diagnosis with serology. In patients without eosinophilia, strongyloidiasis should be considered if living conditions in country of birth put them at risk. As expected, patients had been in the US for many years prior to testing and only 15% of patients were screened by primary care. Increased awareness of the disease must be encouraged, especially amongst primary care physicians. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677805/ http://dx.doi.org/10.1093/ofid/ofad500.141 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Vargas-Pena, Coral N
Alyssa Policarpio, Maria
Chan, Bailey
Kladias, Michael
Coyle, Christina
2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience
title 2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience
title_full 2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience
title_fullStr 2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience
title_full_unstemmed 2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience
title_short 2071. Strongyloides stercoralis Testing in a Hospital in Bronx, NYC; A 3-year Experience
title_sort 2071. strongyloides stercoralis testing in a hospital in bronx, nyc; a 3-year experience
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677805/
http://dx.doi.org/10.1093/ofid/ofad500.141
work_keys_str_mv AT vargaspenacoraln 2071strongyloidesstercoralistestinginahospitalinbronxnyca3yearexperience
AT alyssapolicarpiomaria 2071strongyloidesstercoralistestinginahospitalinbronxnyca3yearexperience
AT chanbailey 2071strongyloidesstercoralistestinginahospitalinbronxnyca3yearexperience
AT kladiasmichael 2071strongyloidesstercoralistestinginahospitalinbronxnyca3yearexperience
AT coylechristina 2071strongyloidesstercoralistestinginahospitalinbronxnyca3yearexperience